Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
about
A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian CancerThe Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review.Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Proteolysis of EphA2 Converts It from a Tumor Suppressor to an OncoproteinInhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.Network analysis identifies an HSP90-central hub susceptible in ovarian cancerTargeting Src in endometriosis-associated ovarian cancerImpact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.Targeting tyrosine-kinases in ovarian cancer.The potential of sunitinib as a therapy in ovarian cancer.Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics.An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.Targeting metastasis.Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cellsScreening drug effects in patient-derived cancer cells links organoid responses to genome alterations.Clinical trials in gynecologic oncology: Past, present, and future.c-Src activity is differentially required by cancer cell motility modes.Expression of c-Src and phospho-Src in epithelial ovarian carcinoma.
P2860
Q28551341-3F081890-DA28-4F2C-B8C0-D0383B5472EDQ30248645-93894E1C-366F-423D-9FD5-37BA1ED78AF7Q35205410-993A4FE7-AC78-47CE-B8B6-2E9C6683ED54Q36380708-D8F05E55-C26F-499D-8D51-6B113C8F9A5BQ36754457-4B7D6A82-F8B6-4817-A94A-EA1F0B1FF813Q37185385-88431335-12CD-4C75-B758-55BD7B754A1EQ37224282-B3C128B9-16F8-430B-927F-9FBF5B742D38Q37337898-88A700DE-1851-413D-BF4D-31317D55EE9CQ37553978-5EA8886A-D314-426A-81D1-50E68D303EF5Q37684642-57DF5D56-A1EE-4CBE-B3F1-42E192EAFC66Q38118388-E2A29639-69F1-4C69-8267-6B4CABA5ACAFQ38144166-9B8301E1-E3B1-4FF5-B4D3-10C66FC44944Q38323440-E0430AAE-35B1-4AE9-9102-D8D507651C90Q38631373-8F415023-F9A5-4C6E-A8FD-A25583385F62Q38786658-32A672D2-0D4F-454B-A569-1948B62C001FQ38815335-381A4DDC-DD62-4274-A322-F74A3B79D4F4Q42676688-E69258D4-CFCC-44AC-9974-4C6F4A11E7F0Q47143099-0DFBA02A-2A96-43C2-A58F-DBAB06FC093BQ47796770-E848A02F-03C5-437D-9B95-315AFB318E1DQ49595076-5F19D165-2403-41E6-BF49-1B3A157C8F61Q50883478-72B270C6-4085-48B7-953A-6015D1FF1256
P2860
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase II evaluation of dasatin ...... ecologic Oncology Group study.
@ast
Phase II evaluation of dasatin ...... ecologic Oncology Group study.
@en
type
label
Phase II evaluation of dasatin ...... ecologic Oncology Group study.
@ast
Phase II evaluation of dasatin ...... ecologic Oncology Group study.
@en
prefLabel
Phase II evaluation of dasatin ...... ecologic Oncology Group study.
@ast
Phase II evaluation of dasatin ...... ecologic Oncology Group study.
@en
P2093
P2860
P1433
P1476
Phase II evaluation of dasatin ...... ecologic Oncology Group study.
@en
P2093
Andrew K Godwin
Anil K Sood
Harsh B Pathak
Heather A Lankes
James V Fiorica
Mark S Shahin
R Katherine Alpaugh
Robert S Mannel
Russell J Schilder
P2860
P356
10.1016/J.YGYNO.2012.06.009
P407
P577
2012-06-16T00:00:00Z